Key result
Losartan possesses potential antiarrhythmogenic properties that may explain its previously reported ability to reduce mortality by 46% compared with captopril in chronic congestive heart failure.
Why the study?
Does losartan reduce mortality and arrhythmias in patients with ischemic heart disease or congestive heart failure?
Population
Patients with ischemic heart disease and/or congestive heart failure
Comparison
Losartan vs Captopril or standard therapy
Design
Review
Authors
Loading...
Supports losartan antiarrhythmic effects in HF; extends RAS inhibition evidence but remains hypothesis-generating.
Does losartan reduce mortality and arrhythmias in patients with ischemic heart disease or congestive heart failure?
This review highlights the potential antiarrhythmic properties of losartan and its role in reducing mortality in heart failure patients.
Gavras et al. (2000) conducted a review in Congestive heart failure and arrhythmias. Losartan vs. Captopril was evaluated. Losartan possesses potential antiarrhythmogenic properties that may explain its previously reported ability to reduce mortality by 46% compared with captopril in chronic congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: